Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation. Dr ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

An expert provided an overview of the promising therapies that are being investigated for the treatment of patients with chronic lymphocytic leukemia. There are many new agents being investigated for ...

This interview was originally published as part of MDEdge's Blood & Cancer podcast series. In this episode, Anthony R. Mato, MD, and Lindsey Roeker, MD, both of Memorial Sloan Kettering Cancer Center ...

In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has positive data suggesting two fixed-duration combinations containing its ...

“This study demonstrates that a PA intervention utilizing aerobic exercise can increase leisure time PA and decrease fatigue in older adult patients with CLL, and that these changes are correlated to ...

Researchers sought to determine whether fixed-duration treatment with venetoclax + obinutuzumab/ibrutinib would have similar efficacy to continuous ibrutinib therapy in CLL.